Reuters logo
BRIEF-Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma
May 2, 2017 / 7:48 PM / 7 months ago

BRIEF-Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma

May 2 (Reuters) - Roche Holding Ag :

* Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma

* Continues to pursue regulatory approval for Ventana PD-L1 (SP263) assay in other cancer indications in US and in other geographies Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below